Related Concept Videos
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Depressive Disorders: MDD and Dysthymia
Bipolar Disorder
Drug Therapy
Antianxiety Medications
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Related Experiment Video
Updated: Jul 3, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Mixed Symptoms in Mood Disorders: A Historical, Clinical, and Therapeutic Review
Gustavo Vázquez1, Verónica Grasso2, Micaela Dines3
1Department of Psychiatry, School of Medicine and Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada. International Consortium for Mood & Psychotic Disorder Research, McLean Hospital, Belmont, MA, EE. UU. . g.vazquez@queensu.ca.
Mixed features in mood disorders, combining manic and depressive symptoms, are common and linked to severe outcomes. Recent research highlights second-generation antipsychotics as effective treatments, unlike older medications or antidepressants.
Area of Science:
- Psychiatry and Mental Health
- Mood Disorders Research
- Pharmacological Treatments
Background:
- Mixed features, blending manic/hypomanic and depressive symptoms, are a core aspect of mood disorders.
- Diagnostic criteria have evolved from restrictive to dimensional approaches, with DSM-5 introducing a 'mixed features' specifier, though limitations remain.
- Recent systematic reviews indicate mixed features are prevalent, affecting 18-35% of major depressive, bipolar depressive, and manic/hypomanic episodes.
Purpose of the Study:
- To review the historical context, epidemiological findings, and recent therapeutic evidence for mixed features in mood disorders.
- To highlight the clinical significance and challenges associated with diagnosing and treating mixed features.
- To underscore the need for improved diagnostic consensus and long-term controlled trials.
Main Methods:
- Systematic review of historical diagnostic formulations and current literature on mixed features.
- Analysis of epidemiological data on prevalence across different mood episode types.
- Evaluation of pharmacological evidence, focusing on recent trials of second-generation antipsychotics and other treatments.
Main Results:
- Mixed features are associated with increased suicide risk, poorer prognosis, and reduced treatment response.
- Second-generation antipsychotics (lumateperone, lurasidone, ziprasidone, cariprazine, olanzapine/fluoxetine) show the most robust evidence for treating mixed features.
- Established mood stabilizers (lithium, valproate, lamotrigine) lack specific studies for mixed depressive episodes, and antidepressant monotherapy is insufficiently supported.
Conclusions:
- Current diagnostic criteria for mixed features require refinement for greater sensitivity.
- There is a critical need for more long-term, controlled clinical trials to guide treatment strategies for mixed features.
- Optimizing the diagnosis and treatment of mixed features is essential for improving patient outcomes in mood disorders.

